Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Pediatr Blood Cancer. 2016 May 16;63(9):1608–1614. doi: 10.1002/pbc.26061

TABLE II.

Late Toxicities After Head and Neck Intensity Modulated Radiation Therapy for Pediatric Rhabdomyosarcoma

Late Toxicity No. of Evaluable Patients Any Grade No. (%) Grade 1 No. Grade 2 No. Grade 3 No. Grade 4 No.
Facial disfigurement 30 23 (76.7) - - - -
Growth hormone deficiency 30 11 (36.7) 1 9 0 0
Cataract 29 10 (34.5) 7 2 0 0
Dental problems 30 10 (33.3) - - - -
Psychological/behavioral problems 30 9 (33.0) 6 3 0 0
Central hypothyroidism 29 7 (24.1) 0 6 0 0
Chronic sinusitis 30 7 (23.3) 3 3 1 0
Chronic otitis 30 6 (20.0) 1 2 3 0
Hearing loss 30 6 (20.0) 0 3 2 0
Visual disturbance 30 6 (20.0) 3 1 2 0
Trismus 30 4 (13.3) 4 0 0 0
Epistaxis 30 4 (13.3) 4 0 0 0
Cognitive deficits 30 4 (13.3) 3 0 0 0
ACTH deficiency 30 4 (13.3) 0 3 0 0
LH/FSH deficiency 30 4 (13.3) 1 2 0 0
Primary hypothyroidism 29 3 (10.3) 0 3 0 0
Nasal congestion 30 3 (10.0) 3 0 0 0
Ptosis 30 2 (6.7) 0 0 2 0
Voice changes 30 2 (6.7) 2 0 0 0
Secondary malignancy 30 2 (6.7) 0 0 0 2
Thyroid nodule 28 1 (3.6) 1 0 0 0
Glaucoma 30 1 (3.3) 1 0 0 0
Amblyopia 30 1 (3.3) 1 0 0 0
Schwannoma 30 1 (3.3) 1 0 0 0